Financial Year 2025 Preliminary Results
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
27 August 2025
Financial Year 2025 Preliminary Results
Biome reports breakthrough year:
● Records its first net profit after tax of $214,656
● Achieved $18.4m in sales revenue, up 41.6%
● June quarter sales revenue exceeded $5m
● International sales reached $1.5m, up ~69%
○ Transformative deals in key international markets to support FY26
growth and scale
● New brand launch and 7 novel products launched in June 2025
● EBITDA* (excluding share-based payments) $931k
● Gross profit reached $11.25m
● Gross margin increased to 61.1%
● On track to achieve Vision 27 forecast cumulative sales of at least $75m for
FY25-27
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the
company’) is pleased to announce unaudited full-year sales revenue of $18.4
million for FY25, representing 41.6% growth versus the previous corresponding
period ($13.01m FY24) and its first net profit after tax of $214,656.
Biome achieved a historic milestone in FY25, delivering its first full year of net
profit since the company's founding in 2018. The breakthrough year
demonstrated exceptional growth across all key metrics, highlighted by annual
sales revenue reaching new records and outpacing category growth by 7-10
times.
Key Financial Highlights
The company maintained strong profitability with its sixth consecutive quarter of
positive EBITDA, achieving full-year EBITDA* of $931k while increasing gross
margin to 61.1%. Q4 FY25 marked the strongest quarter to date with sales revenue
surpassing $5 million, culminating in a record monthly performance of $2.1
million in June. As FY26 commenced, Biome established an annualised sales
revenue run rate of over $20 million, positioning the company strategically toward
its Vision 27 forecast of achieving at least $75 million in cumulative sales for
FY25-27.
Market Position and Growth
Biome's Activated Probiotics brand secured the number two position in total
probiotic revenue within community pharmacy (IQVIA community pharmacy
scan sales at June 30), with domestic business sell-through increasing by over
50% in FY25. This performance established Biome as the category's leading
growth brand, achieved through industry-leading customer service, novel health
targeted product offering and unmatched clinical backing.
International Expansion
International operations delivered significant growth with $1.5 million in
international sales revenue, representing 69% growth versus the previous
corresponding period. Strategic expansion across Canada, Ireland, United
Kingdom, and New Zealand resulted in transformational distribution partnerships
providing access to thousands of additional pharmacy and health food locations
ready for launch in early FY26.
Key partnerships include major Canadian health retailers (Pure Pharmacy Group,
Healthy Planet Group, Nature's Emporium, Nature's Signature), Uniphar in Ireland
(serving over 1,400 pharmacy customers), and Propharma in New Zealand (the
country's largest pharmacy wholesale network and EBOS Group subsidiary).
Innovation and Product Development
FY25 marked the launch of Activated Therapeutics, a new practitioner-only range
featuring four specialized products targeting perimenopause, gastrointestinal
repair, acid reflux, and weight management. The company successfully
completed its strain development program, identifying and commercializing
proprietary probiotic strain Lactobacillus plantarum BMB18, now registered with
the German culture bank DSMZ and providing future licensing opportunities.
The culmination of professional education efforts included the second Activated
Probiotics Symposium, attended by hundreds of health professionals, showcasing
research innovations and strengthening industry relationships that contributed
to a strong start for FY26.
Biome Australia's Founder and Managing Director, Blair Vega Norfolk
commented:
"I am absolutely thrilled to announce our first full year of profitability since
founding Biome in 2018. Achieving $18.4 million in revenue with 41% growth while
maintaining our sixth consecutive quarter of positive EBITDA exceeding $931k is
a testament to what we've built.
I'm incredibly proud of our team for securing the number two position in
probiotic revenue within community pharmacy and delivering that record $2.1
million month in June to close FY25. What excites me most is that we've achieved
this through high quality customer service, education and delivering meaningful
health outcomes for our patients and customers.
Our international expansion has been personally rewarding to see unfold, with
69% growth and strategic partnerships now giving us access to thousands of
pharmacy locations and practitioners across four key markets. The launch of our
Activated Therapeutics platform and our proprietary BMB18 strain represents
years of dedication finally coming to fruition in support of innovation and
product development that we will begin to realise in FY26.
With Biome’s $20 million run-rate entering FY26, I'm confident we're on track for
our Vision 27 targets. After seven years of building this business, seeing us
transition into a sustainable, profitable growth company, we are now entering
the next phase to becoming a leading global company in probiotics and
targeted health solutions for many years to come."
-ENDSApproved for release by the Biome Australia board of directors.
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative,
evidence-based live biotherapeutics (probiotics) and complementary medicines, many of
which are supported by clinical research. Biome aims to improve health outcomes and
quality of life, and make its products accessible to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership
with some of the world's leading organisations in microbiome research and development,
Biome produced several unique live biotherapeutic (probiotic) products with innovative
delivery technologies that improve their stability and efficacy to create its flagship range
of complementary medicines: Activated Probiotics®.
Supported by clinical research, including randomised double-blind placebo-controlled
trials, Activated Probiotics help prevent and support the management of various health
concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema
and IBS. Through practitioner-only distribution, Biome is committed to educating health
professionals on the newfound systemic health effects of the gut microbiota, helping
them to provide innovative, evidence-based natural medicines for the management of
some of humanity's most prevalent and chronic health concerns.
For more information visit: www.biomeaustralia.com
Investor Relations
Rechelle Friend
+61 (3) 9017 5800
corporate@biomeaustralia.com
Media enquiries
media@activated.co
Forward looking statements
This release may contain forward looking statements, including but not limited to projections,
guidance on future revenues, earnings, other potential synergies and estimates and the future
performance of Biome (Forward Looking Statements).
Forward Looking Statements are provided as a general guide only and should not be relied upon
as an indication or guarantee of future performance. Actual results, performance or achievements
may differ materially from those expressed or implied in such Forward Looking Statements and
any projections and assumptions on which these Forward Looking Statements are based. Such
statements may assume the success of Biome's business strategies. You are cautioned not to
place undue reliance on Forward Looking Statements.
The Forward Looking Statements are based on information available to Biome as at the date of
this release. Any Forward Looking Statements containing forward looking financial information
provided in this release is for illustrative purposes only and is not represented as being indicative of
Biome's views on its future financial condition and/or performance.
Nothing in this release is a promise or representation as to the future. No representation or
warranty, express or implied, is made as to the accuracy, likelihood of achievement or
reasonableness of any Forward Looking Statements contained in this release. Except as required
by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any
additional or updated information whether as a result of a change in expectations or assumptions,
new information, future events or results or otherwise.
To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in
respect of, and makes no representation or warranty, express or implied as to the fairness,
currency, accuracy, reliability or completeness of information in this release or the accuracy,
likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or
results expressed or implied in any Forward Looking Statements) contained in, implied by, the
information in this release or any part of it, or that this release contains all material information
about Biome or which a prospective investor or purchaser may require in evaluating a possible
investment in Biome or acquisition of securities in Biome.
Investors are strongly cautioned not to place undue reliance on Forward Looking Statements,
particularly in light of the current economic climate and the significant volatility, uncertainty and
disruption caused by the Covid-19 pandemic.
Share your feedback
Discover